Insights
Search Results
Client Highlights
10.01.26
Wilson Sonsini Advises Stripe on Acquisition of Parafin
On September 30, 2026, Stripe, the programmable financial services company, announced that it has agreed to acquire Parafin, a leading embedded financial products platform. Wilson Sonsini Goodrich & Rosati is advising Stripe on the transaction.
Client Highlights
9.29.26
Wilson Sonsini Advises World Labs on $8.2 Billion Acquisition by AMD
On September 28, 2026, AMD, a global semiconductor company, announced it has entered into a definitive agreement to acquire World Labs, an AI model and research lab led by AI pioneer Dr. Fei-Fei Li. The acquisition will bring a world-class team of researchers and model experts to AMD, strengthening its ability to develop AI hardware, software, and systems. Wilson Sonsini Goodrich & Rosati is advising World Labs on the transaction.
Client Highlights
9.18.26
Wilson Sonsini Advises Superhuman on Acquisition of Fathom
On September 14, 2026, Superhuman, an AI productivity platform bringing AI to wherever people work, announced its acquisition of Fathom, an AI meeting partner trusted by hundreds of thousands of companies to capture, search, and act on what happens in meetings. Wilson Sonsini Goodrich & Rosati advised Superhuman on the transaction.
Client Highlights
9.10.26
Wilson Sonsini Advises Blaxel on its Acquisition by Baseten
On September 10, 2026, Baseten, an artificial intelligence inference company, announced that it has acquired Blaxel, an infrastructure company building secure, persistent execution environments for AI agents. The acquisition expands Baseten's platform to bring reliable, secure, and cost-effective infrastructure agents need to run code, use tools, and maintain state. Wilson Sonsini Goodrich & Rosati advised Blaxel on the transaction.
Client Highlights
9.10.26
Wilson Sonsini Advises Copart on Acquisition of ACV
On September 10, 2026, Copart, Inc., a global leader in online vehicle auctions, and ACV, a leading digital automotive marketplace and data services partner for dealers and commercial clients, announced a definitive agreement in which Copart will acquire all outstanding shares of ACV common stock, valued at approximately $1.9 billion. Wilson Sonsini Goodrich & Rosati advised Copart on the transaction.
Client Highlights
9.03.26
Wilson Sonsini Advises Hugging Face on $12.9 Billion Acquisition by NVIDIA
On September 3, 2026, NVIDIA announced that it has agreed to acquire open-source AI platform Hugging Face for $12.9 billion. Together, NVIDIA and Hugging Face plan to scale Hugging Face’s platform, strengthen its infrastructure, and expand access to AI for developers and institutions worldwide. Wilson Sonsini Goodrich & Rosati advised Hugging Face on the transaction.
Client Highlights
8.25.26
Wilson Sonsini Advises Checkr on Acquisition of Truv
On August 18, 2026, Checkr, an AI-powered verification platform for high-stakes decisions, announced the acquisition of Truv, a consumer-permissioned income, employment, and asset verification company. Wilson Sonsini Goodrich & Rosati advised Checkr on the transaction.
Client Highlights
7.29.26
Wilson Sonsini Advises DroneDeploy on $845 Million Acquisition by Procore Technologies
On July 29, 2026, Procore Technologies, a global provider of construction management software, announced it has entered into a definitive agreement to acquire DroneDeploy, a robotics and visual intelligence platform. Procore will acquire DroneDeploy for approximately $845 million in cash, subject to customary purchase price adjustments. Wilson Sonsini Goodrich & Rosati is advising DroneDeploy on the transaction
Client Highlights
7.27.26
Firm Advises Forte Biosciences on $2.2 Billion Acquisition by argenx
On July 27, 2026, argenx, a global immunology innovation company, and Forte Biosciences, a clinical-stage biopharmaceutical company, announced that they have entered into a definitive agreement under which argenx will acquire Forte Biosciences for $77.00 per share in cash, representing a total equity value of approximately $2.2 billion. FB102, Forte Biosciences’ lead program, expands argenx’s portfolio of differentiated immunology medicines, adding a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease and potential to address multiple autoimmune diseases. Wilson Sonsini Goodrich & Rosati advised Forte Biosciences on the transaction.